Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 1, 2026

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.

Ryan P Nolan1, Harish Chintakuntla2

  • 1Halozyme Therapeutics, 12390 El Camino Real, San Diego, CA, 92130, USA. publications@halozyme.com.

Journal of Pharmacokinetics and Pharmacodynamics
|June 29, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigs.

Drug delivery and translational research·2026
Same author

The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis.

Vaccines·2025
Same author

Shifting Extraocular Motility in a Patient With Burkitt Lymphoma.

Ophthalmic plastic and reconstructive surgery·2024
Same author

Atypical Haemorrhagic Presentation of Neuro-Retinitis and Serous Retinal Detachment Secondary to Cat-Scratch Disease.

Neuro-ophthalmology (Aeolus Press)·2024
Same author

The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies.

Journal of controlled release : official journal of the Controlled Release Society·2024
Same author

Modeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20.

Clinical and translational science·2024
Same journal

Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Comparing heavy-tailed residual error models for outlier handling in population PK modeling.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Personalized prophylactic therapy optimization in hemophilia A using a hybrid PK-PD-TTE model and deep RL.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Development of a novel rabeprazole modified release formulation to reduce the dosing frequency: A trial and triumph with physiologically based biopharmaceutics modeling.

Journal of pharmacokinetics and pharmacodynamics·2026
See all related articles

Recombinant human hyaluronidase PH20 (rHuPH20) enables higher subcutaneous (SC) antibody doses, expanding therapeutic options. Operating Space Maps visualize pharmacokinetic simulations, aiding strategic decisions for SC drug development.

Area of Science:

  • Biopharmaceutical development
  • Pharmacokinetics and Drug Metabolism
  • Drug Delivery Systems

Background:

  • Therapeutic antibody dosing is often limited by formulation and administration, restricting dose and schedule flexibility.
  • Subcutaneous (SC) delivery offers convenience but is typically limited by injection volume, necessitating lower doses and more frequent administration.
  • Recombinant human hyaluronidase PH20 (rHuPH20) facilitates high-volume SC delivery, broadening the scope of feasible SC therapeutic regimens.

Purpose of the Study:

  • To introduce Operating Space Maps, a visual pharmacokinetic (PK) simulation framework for evaluating SC drug delivery strategies.
  • To utilize rHuPH20 as a case study to demonstrate the application of Operating Space Maps in optimizing antibody dosing regimens.
  • To provide biopharmaceutical development teams with tools for quantifying the impact of SC-enabling technologies and interpreting PK simulations for decision-making.
Keywords:
AntibodiesDose optimizationDrug deliveryHyaluronidasePharmacokineticsSubcutaneous

More Related Videos

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound
07:34

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound

Published on: July 18, 2020

Related Experiment Videos

Last Updated: Jul 1, 2026

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound
07:34

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound

Published on: July 18, 2020

Main Methods:

  • Development of a two-compartment PK model to simulate antibody regimens.
  • Application of Operating Space Maps to organize and visualize multiple dosing scenarios, including dose-frequency options.
  • Simulation of representative antibody regimens for converting IV to SC with rHuPH20 and extending SC dosing intervals.

Main Results:

  • A 1400 mg SC dose with rHuPH20 demonstrated equivalent average exposure to a 1000 mg IV benchmark regimen, while reducing peak concentration (Cmax) by approximately 50%.
  • The Operating Space Maps framework visually integrates SC delivery constraints and PK parameters (Cmin, Cavg, Cmax) to illustrate trade-offs.
  • The methodology proved effective in evaluating regimen feasibility for both converting IV to SC and extending SC dosing intervals.

Conclusions:

  • Operating Space Maps provide an intuitive landscape for dose-frequency options, enhancing the strategic evaluation of SC delivery technologies.
  • The framework enables cross-functional teams to optimize target product profiles and make informed decisions early in the development process.
  • The methodology is broadly applicable to other SC-enabling technologies, provided sufficient foundational data exists for model parameterization.